Research ArticleClinical Investigation
Open Access
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Tristan R. Grogan, Johannes Czernin, Matthew B. Rettig, Ken Herrmann, Jeremie Calais, Wolfgang A. Weber, Matthias R. Benz, Wolfgang P. Fendler and Matthias Eiber
Journal of Nuclear Medicine November 2022, 63 (11) 1651-1658; DOI: https://doi.org/10.2967/jnumed.121.263072
Andrei Gafita
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
2Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Isabel Rauscher
2Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Manuel Weber
3Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
Boris Hadaschik
4Department of Urology, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
Hui Wang
2Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Wesley R. Armstrong
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
Robert Tauber
5Department of Urology, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Tristan R. Grogan
6Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California; and
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
Matthew B. Rettig
7Department of Urology, David Geffen School of Medicine, UCLA, Los Angeles, California
Ken Herrmann
3Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
Wolfgang A. Weber
2Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Matthias R. Benz
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
Wolfgang P. Fendler
3Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
Matthias Eiber
2Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 11
November 1, 2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Tristan R. Grogan, Johannes Czernin, Matthew B. Rettig, Ken Herrmann, Jeremie Calais, Wolfgang A. Weber, Matthias R. Benz, Wolfgang P. Fendler, Matthias Eiber
Journal of Nuclear Medicine Nov 2022, 63 (11) 1651-1658; DOI: 10.2967/jnumed.121.263072
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Tristan R. Grogan, Johannes Czernin, Matthew B. Rettig, Ken Herrmann, Jeremie Calais, Wolfgang A. Weber, Matthias R. Benz, Wolfgang P. Fendler, Matthias Eiber
Journal of Nuclear Medicine Nov 2022, 63 (11) 1651-1658; DOI: 10.2967/jnumed.121.263072
Jump to section
Related Articles
Cited By...
- RECIP 1.0: A Roadmap for Clinical Implementation
- Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
- SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy
- The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy
- Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer
- SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617
- Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy
- Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
- RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T
- Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
- First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
- PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
- A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
- Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)